Haupt Pharma Muenster GmbH – FDA 483, Jul 6, 2018
An FDA inspection of Haupt Pharma Muenster GmbH in Munster, Germany, revealed significant deficiencies in their quality control unit, including inadequate failure investigations and stability testing reviews. The firm also lacked appropriate controls over electronic data systems, compromising data integrity, and failed to establish written procedures for critical production and process controls, particularly for contract analytical testing. These observations indicate a need for comprehensive improvements in their quality management system.
ID · e06ebb4d-b570-4c24-ae58-d40d5dbe6135
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.